Pipeline Therapeutics Signs Licensing Agreement with Janssen for Investigational Neurotherapeutic, PIPE-307

By Shweta Gupta

Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)

Published: 11 May-2023

DOI: 10.3833/pdr.v2023.i5.2782     ISSN: 1756-7874

Section: Licensing



In a bid to bolster its neuroscience portfolio, Janssen has entered into a global license and development agreement with Pipeline Therapeutics for the investigational compound, PIPE-307, to treat nervous system disorders...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details